ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025
Immunoexpression of CXCL12 and CXCR4 in oral tongue squamous cell carcinoma of young and older patients.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study analyzed the immunoexpression of C-X-C chemokine ligand 12 (CXCL12) and C-X-C chemokine receptor 4 (CXCR4) in oral tongue squamous cell carcinoma (OTSCC) of young (≤ 45 years) and older (≥ 60 years) patients and correlated the findings with clinicopathological parameters (sex, tumor size, regional metastasis, clinical stage, and histopathological grade of malignancy).
methodsForty OTSCC cases (20 diagnosed in young patients and 20 diagnosed in older patients) were selected. Cytoplasmic (CXCL12 and CXCR4) and nuclear (CXCR4) staining percentages in epithelial and stromal cells were assessed at the invasive tumor front.
resultsLow median percentages of CXCL12 positivity were observed in epithelial and stromal cells of OTSCC in both age groups. In stromal cells, expression of this chemokine was higher in older individuals compared to young individuals (p = 0.026). Expression of CXCR4 in neoplastic cells was more frequent in older individuals, with higher median percentages of cytoplasmic (p = 0.023) and nuclear (p = 0.001) positivity compared to young individuals. In stromal cells, older individuals exhibited a significantly higher cytoplasmic expression of CXCR4 (p < 0.001). No significant differences in CXCL12 or CXCR4 immunoexpression according to clinicopathological parameters was observed in either age group (p > 0.05). Positive correlations between cytoplasmic and nuclear expressions of CXCR4 were found in young (r = 0.580; p = 0.007) and older individuals (r = 0.476;p = 0.034).
conclusionThe results suggest the participation of CXCR4 in the development of OTSCC, especially in older individuals. The findings also support possible age-related differences in the pathogenesis of this malignant neoplasm. Nevertheless, this protein may not be involved in the progression of OTSCC.
Indexed as
Identifiers
39613853What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.